The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2019 | U2′ regimen with checkpoint inhibition in R/R CLL and Richter’s transformation
Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, highlights data from the Phase I/II triple therapy study of umbralisib and ublituximab (‘U2’) combined with checkpoint inhibition in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and Richter’s transformation. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
